SCHEMBL2652896

SCHEMBL2652896

CS(=O)(=O)c1ccc(C2(C(=O)O)CC2C2CCCCC2)cc1OC(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.39
ADAMTS4 O75173 1/20 0.32
KCNN4 O15554 2/20 0.32
HSD11B1 P28845 1/20 0.32
HSD11B2 P80365 1/20 0.32
OPRM1 P35372 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
PAX8 Q06710 1/20 0.31
CACNA1B Q00975 2/20 0.31
CYP3A4 P08684 1/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
KCNH2 Q12809 1/20 0.30
TMEM97 Q5BJF2 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1581888 0.84 GCK (0.41) GCKCNR1CNR2EPHX2
SCHEMBL1582120 0.83 GCK (0.42) GCKCYP3A4CNR2KCNH2EPHX2
SCHEMBL2654751 0.82 SLC6A4 (0.34) GCKKCNN4OPRM1PAX8CNR1
SCHEMBL13757063 0.81 GCK (0.68) GCKKCNH2ALDH1A1LMNA
SCHEMBL13757080 0.81 GCK (0.50) GCKALDH1A1LMNA
SCHEMBL2652793 0.81 GCK (0.68) GCKKCNH2ALDH1A1LMNA
SCHEMBL2656522 0.76 CNR2 (0.39) GCKADAMTS4CNR1CNR2EPHX2
SCHEMBL1581747 0.75 GCK (0.60) GCKHSD11B1CNR2ALDH1A1EPHX2
SCHEMBL2654841 0.75 GCK (0.60) GCKHSD11B1CNR2ALDH1A1EPHX2
SCHEMBL1582235 0.74 GCK (0.58) GCKHSD11B1CNR2ALDH1A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 GCK 1/4885ADAMTS4 3984/4885KCNN4 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.